Why the study?
How should dabigatran and other new oral anticoagulants be used for stroke prevention in patients with atrial fibrillation compared to vitamin K antagonists?
Population
Patients with atrial fibrillation
Comparison
Dabigatran and other new oral anticoagulants (OAC) vs Vitamin K antagonists (VKAs)
Design
Guideline
Authors
Loading...
May ease monitoring burden for AF patients; leaves open need for targeted risk-stratified validation.
How should dabigatran and other new oral anticoagulants be used for stroke prevention in patients with atrial fibrillation compared to vitamin K antagonists?
This report provides expert consensus answers to practical clinical questions regarding the use of new oral anticoagulants for stroke prevention in atrial fibrillation.
Crippa et al. (2011) conducted a review in Atrial fibrillation. Dabigatran and other new oral anticoagulants vs. Vitamin K antagonists was evaluated. Dabigatran and other new oral anticoagulants represent an alternative to vitamin K antagonists for stroke prevention in atrial fibrillation without the burden of laboratory control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: